Artificial Intelligence impact on decision-making regarding short-term ADT with prostate radiotherapy: ASTuTE clinical trial interim results

  1. Eric Wegener
  2. Michael Ng
  3. Mario Guerrieri
  4. Timothy N. Showalter
  5. Jeremy Leon
  6. Sagar Ramani
  7. Marcus Dreosti
  8. Tee Lim
  9. Bradley Wong
  10. Annie Ho
  11. Michael Chao
  12. Zachary Wilczynski
  13. Peter Chong
  14. Scott McClintock
  15. Darren Foreman
  16. Matthew Brown
  17. Stephen McCombie
  18. Kevin McMillan
  19. Marcus Handmer
  20. Mark Frydenberg
  21. Lih-Ming Wong
  22. Dickon Hayne
  23. John Yaxley
  24. Phillip Stricker
  25. Jarad Martin
Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Short-term androgen deprivation therapy (ST-ADT) improves outcomes for intermediate-risk prostate cancer (IR-PC) but has toxicity. This trial assesses multimodal AI (MMAI) biomarkers in ST-ADT decision-making for men receiving radiotherapy. We report interim results from 200 patients. MMAI testing significantly impacted shared decisions, with 70.3% of patients initially opting for ST-ADT changing decision to forgo ADT (p<0.001). Use of these biomarkers have led to reduced ST-ADT use and better-informed management.

Article activity feed

  1. Version published to 10.21203/rs.3.rs-7210927/v1 on Research Square